Skip to content
DataLookout
Menu

NCT03910660

A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype

StatusCompleted
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 21 versions: 19 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 10, 2026 Show 11 more changesShow less
    • Start date: Feb 12, 2019 to Jun 10, 2019
    • Eligibility criteria expanded, about 69 words
    • Primary endpoints revised (2)
    • Enrollment target: 98 to 97
    • Interventions: BXCL701 monotherapy (Drug), BXCL701 plus Pembrolizumab (Drug) to Pembrolizumab (Drug), Talabostat (Drug)
    • Secondary endpoints: 8 to 17
    • Study description shortened, about 101 words
    • Site details revised at 1 of 12 sites
    • Publications: details revised at 1 of 1 entry
    • Study arms: 4 to 7
    • Study title expanded, about 5 words
  2. Minor Study completion date: Dec 12, 2024 to Aug 31, 2025v20
  3. Minor Trial status: Active, Not Recruiting to Completed
    • Primary completion date changed from estimate of Oct 2023 to Oct 31, 2023
    • Study completion date changed from estimate of Dec 2025 to Dec 12, 2024
    v19
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 240 to confirmed 98
    • Site details revised at 12 of 12 sites
    v18
  5. Notable Enrollment target: 135 to 240
    • Primary completion date: Jun 2, 2022 to Oct 2023
    • Study completion date: Jun 2, 2022 to Dec 2025
    • Study sites revised (12)
    v17
Show 13 earlier versionsHide 13 earlier versions
  1. Minor Primary completion date: Apr 2, 2022 to Jun 2, 2022v16
  2. Notable Enrollment target: 60 to 135v15
  3. Notable Enrollment target: 40 to 60v14 Show 7 more changesShow less
    • Eligibility criteria expanded, about 7 words
    • Primary endpoints: 1 to 2
    • Interventions: Talabostat Mesylate plus Pembrolizumab (Drug) to BXCL701 monotherapy (Drug), BXCL701 plus Pembrolizumab (Drug)
    • Secondary endpoints: 5 to 8
    • Study description expanded, about 132 words
    • Study title expanded, about 9 words
    • Study arms: 2 to 4
  4. Minor Study sites: 11 to 12v12
  5. Notable Eligibility criteria expanded, about 64 wordsv11
  6. Notable Eligibility criteria expanded, about 194 wordsv10 Show 5 more changesShow less
    • Primary endpoint revised
    • Study sites: 10 to 11
    • Secondary endpoints revised (5)
    • Study description expanded, about 52 words
    • Study title shortened, about 4 words
  7. Minor Study sites: 8 to 10v9
  8. Notable Eligibility criteria expanded, about 60 wordsv8
  9. Notable Eligibility criteria expanded, about 50 words
    • Study description expanded, about 15 words
    v7
  10. Minor Study sites: 7 to 8v6
  11. Minor Site contacts updated at 7 of 7 sitesv5
  12. Minor Study sites: 5 to 7v4
  13. Minor Study sites: 2 to 5v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 2a: Composite Response Rate (CRR)
Timeframe: Up to approximately 4 years and 4 months
Phase 2b: Objective Response Rate (ORR)
Timeframe: Up to approximately 4 years and 4 months

Secondary (17)

Phase 2a: Radiographic Progression-free Survival (rPFS)
Phase 2a: Prostate Specific Antigen (PSA) Progression-free Survival (PFS)
Phase 2a: Overall Survival (OS)
Phase 2a: Duration of Response (DOR)
Phase 2a: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Show 12 moreShow less
Phase 2a: ≥50% Decline in PSA Value From Baseline (PSA50) Duration of Response (PSA50 DOR)
Phase 2a: Duration of Stable Disease
Phase 2b: Number of Participants With PSA Decline From Baseline of at Least 50%
Phase 2b: CRR
Phase 2b: rPFS
Phase 2b: PSA PFS
Phase 2b: OS
Phase 2b: DOR
Phase 2b: PSA50 DOR
Phase 2b: Duration of Stable Disease
Phase 2a: Plasma Concentration of Talabostat
Phase 2a: Concentration of Plasma Cytokines

Arms and interventions

Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mgExperimental

Participants will receive the combination of talabostat 0.4 mg QD orally on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mgExperimental

Participants will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mgExperimental

Participants will receive the combination of talabostat 0.3 mg twice daily (BID) (at a total daily dose \[TDD\] of 0.6 mg) orally on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mgExperimental

Participants with SCNC will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgExperimental

Participants with adenocarcinoma will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgExperimental

Participants with adenocarcinoma will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

Phase 2B (Adenocarcinoma): Talabostat MonotherapyExperimental

Participants with adenocarcinoma will receive talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

Drugs: Talabostat, Pembrolizumab

Sites

12 sites in 2 countries

United States 9, United Kingdom 3